APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Vaccine Contract Manufacturing

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Human Vaccine Contract Manufacturing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 May 2026195 pages

Choose your research edition.

Industry ResearchHuman Vaccine Contract Manufacturing Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Vaccine Contract Manufacturing Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Human Vaccine Contract Manufacturing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Vaccine Contract Manufacturing Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Vaccine Contract Manufacturing Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Human Vaccine Contract Manufacturing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Human Vaccine Contract Manufacturing include Lonza, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc. and PRA Health Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Human Vaccine Contract Manufacturing market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Vaccine Contract Manufacturing and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Vaccine Contract Manufacturing revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Human Vaccine Contract Manufacturing market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Vaccine Contract Manufacturing Segment by Company

Lonza

Fujifilm Diosynth Biotechnologies U.S.A., Inc.

Ajinomoto Althea, Inc.

Merck KgaA

Cytovance Biologics

Catalent, Inc.

IDT Biologika GmbH

Albany Molecular Research, Inc.

PRA Health Sciences

ICON plc.

Pharmaceutical Product Development, LLC

Cobra Bio

Paragon Bioservices, Inc.

Emergent BioSolutions Inc.

CSL Limited

BioNTech SE

Wuxi Biologics

Samsung Biologics

Boehringer Ingelheim

Novavax, Inc.

Human Vaccine Contract Manufacturing Segment by Type

Attenuated

Inactivated

Subunit-based

Toxoid-based

DNA-based

Human Vaccine Contract Manufacturing Segment by Application

Downstream

Upstream

Human Vaccine Contract Manufacturing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Vaccine Contract Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Vaccine Contract Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Vaccine Contract Manufacturing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Human Vaccine Contract Manufacturing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Vaccine Contract Manufacturing industry.

Chapter 3: Detailed analysis of Human Vaccine Contract Manufacturing companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Vaccine Contract Manufacturingrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Attenuated Table 3. Key Players of Inactivated Table 4. Key Players of Subunit-based Table 3. Key Players of Toxoid-based Table 4. Key Players of DNA-based Table 5. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Downstream Table 7. Key Players of Upstream Table 8. Global Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Human Vaccine Contract Manufacturing Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Human Vaccine Contract Manufacturing Market Share by Region (2021-2026) Table 11. Global Human Vaccine Contract Manufacturing Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Human Vaccine Contract Manufacturing Market Share by Region (2027-2032) Table 13. Human Vaccine Contract Manufacturing Industry Trends Table 14. Human Vaccine Contract Manufacturing Industry Drivers Table 15. Human Vaccine Contract Manufacturing Industry Opportunities and Challenges Table 16. Human Vaccine Contract Manufacturing Industry Restraints Table 17. Global Human Vaccine Contract Manufacturing Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Human Vaccine Contract Manufacturing Revenue Market Share by Company (2021-2026) Table 19. Global Human Vaccine Contract Manufacturing Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Human Vaccine Contract Manufacturing Key Company Head Office and Area Served Table 21. Global Human Vaccine Contract Manufacturing Company, Product Type & Application Table 22. Global Human Vaccine Contract Manufacturing Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Human Vaccine Contract Manufacturing by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Human Vaccine Contract Manufacturing Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Human Vaccine Contract Manufacturing Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Human Vaccine Contract Manufacturing Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2021-2026) Table 29. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2027-2032) Table 30. Global Human Vaccine Contract Manufacturing Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Human Vaccine Contract Manufacturing Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Human Vaccine Contract Manufacturing Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2021-2026) Table 34. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2027-2032) Table 35. Lonza Company Information Table 36. Lonza Business Overview Table 37. Lonza Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Lonza Human Vaccine Contract Manufacturing Product Portfolio Table 39. Lonza Recent Development Table 40. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information Table 41. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview Table 42. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 44. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Development Table 45. Ajinomoto Althea, Inc. Company Information Table 46. Ajinomoto Althea, Inc. Business Overview Table 47. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 49. Ajinomoto Althea, Inc. Recent Development Table 50. Merck KgaA Company Information Table 51. Merck KgaA Business Overview Table 52. Merck KgaA Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio Table 54. Merck KgaA Recent Development Table 55. Cytovance Biologics Company Information Table 56. Cytovance Biologics Business Overview Table 57. Cytovance Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 59. Cytovance Biologics Recent Development Table 60. Catalent, Inc. Company Information Table 61. Catalent, Inc. Business Overview Table 62. Catalent, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 64. Catalent, Inc. Recent Development Table 65. IDT Biologika GmbH Company Information Table 66. IDT Biologika GmbH Business Overview Table 67. IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio Table 69. IDT Biologika GmbH Recent Development Table 70. Albany Molecular Research, Inc. Company Information Table 71. Albany Molecular Research, Inc. Business Overview Table 72. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 74. Albany Molecular Research, Inc. Recent Development Table 75. PRA Health Sciences Company Information Table 76. PRA Health Sciences Business Overview Table 77. PRA Health Sciences Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio Table 79. PRA Health Sciences Recent Development Table 80. ICON plc. Company Information Table 81. ICON plc. Business Overview Table 82. ICON plc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. ICON plc. Human Vaccine Contract Manufacturing Product Portfolio Table 84. ICON plc. Recent Development Table 85. Pharmaceutical Product Development, LLC Company Information Table 86. Pharmaceutical Product Development, LLC Business Overview Table 87. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio Table 89. Pharmaceutical Product Development, LLC Recent Development Table 90. Cobra Bio Company Information Table 91. Cobra Bio Business Overview Table 92. Cobra Bio Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio Table 94. Cobra Bio Recent Development Table 95. Paragon Bioservices, Inc. Company Information Table 96. Paragon Bioservices, Inc. Business Overview Table 97. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 99. Paragon Bioservices, Inc. Recent Development Table 100. Emergent BioSolutions Inc. Company Information Table 101. Emergent BioSolutions Inc. Business Overview Table 102. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 104. Emergent BioSolutions Inc. Recent Development Table 105. CSL Limited Company Information Table 106. CSL Limited Business Overview Table 107. CSL Limited Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 108. CSL Limited Human Vaccine Contract Manufacturing Product Portfolio Table 109. CSL Limited Recent Development Table 110. BioNTech SE Company Information Table 111. BioNTech SE Business Overview Table 112. BioNTech SE Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 113. BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio Table 114. BioNTech SE Recent Development Table 115. Wuxi Biologics Company Information Table 116. Wuxi Biologics Business Overview Table 117. Wuxi Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 118. Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 119. Wuxi Biologics Recent Development Table 120. Samsung Biologics Company Information Table 121. Samsung Biologics Business Overview Table 122. Samsung Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 123. Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 124. Samsung Biologics Recent Development Table 125. Boehringer Ingelheim Company Information Table 126. Boehringer Ingelheim Business Overview Table 127. Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 128. Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio Table 129. Boehringer Ingelheim Recent Development Table 130. Novavax, Inc. Company Information Table 131. Novavax, Inc. Business Overview Table 132. Novavax, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 133. Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 134. Novavax, Inc. Recent Development Table 135. North America Human Vaccine Contract Manufacturing Market Size by Type (2021-2026) & (US$ Million) Table 136. North America Human Vaccine Contract Manufacturing Market Size by Type (2027-2032) & (US$ Million) Table 137. North America Human Vaccine Contract Manufacturing Market Size by Application (2021-2026) & (US$ Million) Table 138. North America Human Vaccine Contract Manufacturing Market Size by Application (2027-2032) & (US$ Million) Table 139. North America Human Vaccine Contract Manufacturing Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) Table 141. North America Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) Table 142. Europe Human Vaccine Contract Manufacturing Market Size by Type (2021-2026) & (US$ Million) Table 143. Europe Human Vaccine Contract Manufacturing Market Size by Type (2027-2032) & (US$ Million) Table 144. Europe Human Vaccine Contract Manufacturing Market Size by Application (2021-2026) & (US$ Million) Table 145. Europe Human Vaccine Contract Manufacturing Market Size by Application (2027-2032) & (US$ Million) Table 146. Europe Human Vaccine Contract Manufacturing Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Europe Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) Table 148. Europe Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) Table 149. China Human Vaccine Contract Manufacturing Market Size by Type (2021-2026) & (US$ Million) Table 150. China Human Vaccine Contract Manufacturing Market Size by Type (2027-2032) & (US$ Million) Table 151. China Human Vaccine Contract Manufacturing Market Size by Application (2021-2026) & (US$ Million) Table 152. China Human Vaccine Contract Manufacturing Market Size by Application (2027-2032) & (US$ Million) Table 153. Asia Human Vaccine Contract Manufacturing Market Size by Type (2021-2026) & (US$ Million) Table 154. Asia Human Vaccine Contract Manufacturing Market Size by Type (2027-2032) & (US$ Million) Table 155. Asia Human Vaccine Contract Manufacturing Market Size by Application (2021-2026) & (US$ Million) Table 156. Asia Human Vaccine Contract Manufacturing Market Size by Application (2027-2032) & (US$ Million) Table 157. Asia Human Vaccine Contract Manufacturing Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Asia Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) Table 159. Asia Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) Table 160. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Type (2021-2026) & (US$ Million) Table 161. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Type (2027-2032) & (US$ Million) Table 162. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Application (2021-2026) & (US$ Million) Table 163. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Application (2027-2032) & (US$ Million) Table 164. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) Table 166. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Human Vaccine Contract Manufacturing Product Image Figure 2. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Human Vaccine Contract Manufacturing Market Share by Type: 2025 VS 2032 Figure 4. Attenuated Image Figure 5. Inactivated Image Figure 6. Subunit-based Image Figure 7. Toxoid-based Image Figure 8. DNA-based Image Figure 9. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Human Vaccine Contract Manufacturing Market Share by Application: 2025 VS 2032 Figure 11. Downstream Image Figure 12. Upstream Image Figure 13. Global Human Vaccine Contract Manufacturing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 15. Global Human Vaccine Contract Manufacturing Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Human Vaccine Contract Manufacturing Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Human Vaccine Contract Manufacturing Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Human Vaccine Contract Manufacturing Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2021-2032) Figure 22. Global Human Vaccine Contract Manufacturing Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2021-2032) Figure 24. North America Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 25. North America Human Vaccine Contract Manufacturing Market Share by Type (2021-2032) Figure 26. North America Human Vaccine Contract Manufacturing Market Share by Application (2021-2032) Figure 27. North America Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 28. United States Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 29. Canada Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 31. Europe Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 32. Europe Human Vaccine Contract Manufacturing Market Share by Type (2021-2032) Figure 33. Europe Human Vaccine Contract Manufacturing Market Share by Application (2021-2032) Figure 34. Europe Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 35. Germany Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 36. France Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 38. Italy Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 39. Russia Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 41. China Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 42. China Human Vaccine Contract Manufacturing Market Share by Type (2021-2032) Figure 43. China Human Vaccine Contract Manufacturing Market Share by Application (2021-2032) Figure 44. Asia Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 45. Asia Human Vaccine Contract Manufacturing Market Share by Type (2021-2032) Figure 46. Asia Human Vaccine Contract Manufacturing Market Share by Application (2021-2032) Figure 47. Asia Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 48. Japan Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 52. India Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 53. Australia Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 58. Brazil Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 63. UAE Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 65. Chile Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based
Applications
  • Downstream
  • Upstream
Companies covered
  • Lonza
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Ajinomoto Althea, Inc.
  • Merck KgaA
  • Cytovance Biologics
  • Catalent, Inc.
  • IDT Biologika GmbH
  • Albany Molecular Research, Inc.
  • PRA Health Sciences
  • ICON plc.
  • Pharmaceutical Product Development, LLC
  • Cobra Bio
  • Paragon Bioservices, Inc.
  • Emergent BioSolutions Inc.
  • CSL Limited
  • BioNTech SE
  • Wuxi Biologics
  • Samsung Biologics
  • Boehringer Ingelheim
  • Novavax, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Attenuated
  5. 1.2.3 Inactivated
  6. 1.2.4 Subunit-based
  7. 1.2.5 Toxoid-based
  8. 1.2.6 DNA-based
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Downstream
  12. 1.3.3 Upstream
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Human Vaccine Contract Manufacturing Growth Trends by Region
  15. 1.5.1 Global Human Vaccine Contract Manufacturing Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Human Vaccine Contract Manufacturing Market Size by Region (2021-2026)
  17. 1.5.3 Human Vaccine Contract Manufacturing Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Human Vaccine Contract Manufacturing Market Dynamics
  1. 2.1 Human Vaccine Contract Manufacturing Industry Trends
  2. 2.2 Human Vaccine Contract Manufacturing Industry Drivers
  3. 2.3 Human Vaccine Contract Manufacturing Industry Opportunities and Challenges
  4. 2.4 Human Vaccine Contract Manufacturing Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Human Vaccine Contract Manufacturing Revenue by Company (2021-2026)
  2. 3.2 Global Human Vaccine Contract Manufacturing Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Human Vaccine Contract Manufacturing Key Company Head office and Area Served
  4. 3.4 Global Human Vaccine Contract Manufacturing Company, Product Type & Application
  5. 3.5 Global Human Vaccine Contract Manufacturing Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Human Vaccine Contract Manufacturing Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Human Vaccine Contract Manufacturing Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Human Vaccine Contract Manufacturing Tier 1, Tier 2, and Tier 3
4 Human Vaccine Contract Manufacturing Market by Type
  1. 4.1 Global Human Vaccine Contract Manufacturing Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Human Vaccine Contract Manufacturing Market Size by Type (2021-2032)
  3. 4.3 Global Human Vaccine Contract Manufacturing Market Size Share by Type (2021-2032)
5 Human Vaccine Contract Manufacturing Market by Application
  1. 5.1 Global Human Vaccine Contract Manufacturing Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Human Vaccine Contract Manufacturing Market Size by Application (2021-2032)
  3. 5.3 Global Human Vaccine Contract Manufacturing Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Lonza
  2. 6.1.1 Lonza Company Information
  3. 6.1.2 Lonza Business Overview
  4. 6.1.3 Lonza Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Lonza Human Vaccine Contract Manufacturing Product Portfolio
  6. 6.1.5 Lonza Recent Developments
  7. 6.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  8. 6.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information
  9. 6.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
  10. 6.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio
  12. 6.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
  13. 6.3 Ajinomoto Althea, Inc.
  14. 6.3.1 Ajinomoto Althea, Inc. Company Information
  15. 6.3.2 Ajinomoto Althea, Inc. Business Overview
  16. 6.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  18. 6.3.5 Ajinomoto Althea, Inc. Recent Developments
  19. 6.4 Merck KgaA
  20. 6.4.1 Merck KgaA Company Information
  21. 6.4.2 Merck KgaA Business Overview
  22. 6.4.3 Merck KgaA Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio
  24. 6.4.5 Merck KgaA Recent Developments
  25. 6.5 Cytovance Biologics
  26. 6.5.1 Cytovance Biologics Company Information
  27. 6.5.2 Cytovance Biologics Business Overview
  28. 6.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio
  30. 6.5.5 Cytovance Biologics Recent Developments
  31. 6.6 Catalent, Inc.
  32. 6.6.1 Catalent, Inc. Company Information
  33. 6.6.2 Catalent, Inc. Business Overview
  34. 6.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  36. 6.6.5 Catalent, Inc. Recent Developments
  37. 6.7 IDT Biologika GmbH
  38. 6.7.1 IDT Biologika GmbH Company Information
  39. 6.7.2 IDT Biologika GmbH Business Overview
  40. 6.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio
  42. 6.7.5 IDT Biologika GmbH Recent Developments
  43. 6.8 Albany Molecular Research, Inc.
  44. 6.8.1 Albany Molecular Research, Inc. Company Information
  45. 6.8.2 Albany Molecular Research, Inc. Business Overview
  46. 6.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  48. 6.8.5 Albany Molecular Research, Inc. Recent Developments
  49. 6.9 PRA Health Sciences
  50. 6.9.1 PRA Health Sciences Company Information
  51. 6.9.2 PRA Health Sciences Business Overview
  52. 6.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio
  54. 6.9.5 PRA Health Sciences Recent Developments
  55. 6.10 ICON plc.
  56. 6.10.1 ICON plc. Company Information
  57. 6.10.2 ICON plc. Business Overview
  58. 6.10.3 ICON plc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 ICON plc. Human Vaccine Contract Manufacturing Product Portfolio
  60. 6.10.5 ICON plc. Recent Developments
  61. 6.11 Pharmaceutical Product Development, LLC
  62. 6.11.1 Pharmaceutical Product Development, LLC Company Information
  63. 6.11.2 Pharmaceutical Product Development, LLC Business Overview
  64. 6.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio
  66. 6.11.5 Pharmaceutical Product Development, LLC Recent Developments
  67. 6.12 Cobra Bio
  68. 6.12.1 Cobra Bio Company Information
  69. 6.12.2 Cobra Bio Business Overview
  70. 6.12.3 Cobra Bio Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio
  72. 6.12.5 Cobra Bio Recent Developments
  73. 6.13 Paragon Bioservices, Inc.
  74. 6.13.1 Paragon Bioservices, Inc. Company Information
  75. 6.13.2 Paragon Bioservices, Inc. Business Overview
  76. 6.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  78. 6.13.5 Paragon Bioservices, Inc. Recent Developments
  79. 6.14 Emergent BioSolutions Inc.
  80. 6.14.1 Emergent BioSolutions Inc. Company Information
  81. 6.14.2 Emergent BioSolutions Inc. Business Overview
  82. 6.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio
  84. 6.14.5 Emergent BioSolutions Inc. Recent Developments
  85. 6.15 CSL Limited
  86. 6.15.1 CSL Limited Company Information
  87. 6.15.2 CSL Limited Business Overview
  88. 6.15.3 CSL Limited Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 CSL Limited Human Vaccine Contract Manufacturing Product Portfolio
  90. 6.15.5 CSL Limited Recent Developments
  91. 6.16 BioNTech SE
  92. 6.16.1 BioNTech SE Company Information
  93. 6.16.2 BioNTech SE Business Overview
  94. 6.16.3 BioNTech SE Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio
  96. 6.16.5 BioNTech SE Recent Developments
  97. 6.17 Wuxi Biologics
  98. 6.17.1 Wuxi Biologics Company Information
  99. 6.17.2 Wuxi Biologics Business Overview
  100. 6.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio
  102. 6.17.5 Wuxi Biologics Recent Developments
  103. 6.18 Samsung Biologics
  104. 6.18.1 Samsung Biologics Company Information
  105. 6.18.2 Samsung Biologics Business Overview
  106. 6.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio
  108. 6.18.5 Samsung Biologics Recent Developments
  109. 6.19 Boehringer Ingelheim
  110. 6.19.1 Boehringer Ingelheim Company Information
  111. 6.19.2 Boehringer Ingelheim Business Overview
  112. 6.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio
  114. 6.19.5 Boehringer Ingelheim Recent Developments
  115. 6.20 Novavax, Inc.
  116. 6.20.1 Novavax, Inc. Company Information
  117. 6.20.2 Novavax, Inc. Business Overview
  118. 6.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  120. 6.20.5 Novavax, Inc. Recent Developments
7 North America
  1. 7.1 North America Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 7.2 North America Human Vaccine Contract Manufacturing Market Size by Type
  3. 7.2.1 North America Human Vaccine Contract Manufacturing Market Size by Type (2021-2026)
  4. 7.2.2 North America Human Vaccine Contract Manufacturing Market Size by Type (2027-2032)
  5. 7.2.3 North America Human Vaccine Contract Manufacturing Market Share by Type (2021-2032)
  6. 7.3 North America Human Vaccine Contract Manufacturing Market Size by Application
  7. 7.3.1 North America Human Vaccine Contract Manufacturing Market Size by Application (2021-2026)
  8. 7.3.2 North America Human Vaccine Contract Manufacturing Market Size by Application (2027-2032)
  9. 7.3.3 North America Human Vaccine Contract Manufacturing Market Share by Application (2021-2032)
  10. 7.4 North America Human Vaccine Contract Manufacturing Market Size by Country
  11. 7.4.1 North America Human Vaccine Contract Manufacturing Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  13. 7.4.3 North America Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  14. 7.4.4 North America Human Vaccine Contract Manufacturing Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 8.2 Europe Human Vaccine Contract Manufacturing Market Size by Type
  3. 8.2.1 Europe Human Vaccine Contract Manufacturing Market Size by Type (2021-2026)
  4. 8.2.2 Europe Human Vaccine Contract Manufacturing Market Size by Type (2027-2032)
  5. 8.2.3 Europe Human Vaccine Contract Manufacturing Market Share by Type (2021-2032)
  6. 8.3 Europe Human Vaccine Contract Manufacturing Market Size by Application
  7. 8.3.1 Europe Human Vaccine Contract Manufacturing Market Size by Application (2021-2026)
  8. 8.3.2 Europe Human Vaccine Contract Manufacturing Market Size by Application (2027-2032)
  9. 8.3.3 Europe Human Vaccine Contract Manufacturing Market Share by Application (2021-2032)
  10. 8.4 Europe Human Vaccine Contract Manufacturing Market Size by Country
  11. 8.4.1 Europe Human Vaccine Contract Manufacturing Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  13. 8.4.3 Europe Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  14. 8.4.4 Europe Human Vaccine Contract Manufacturing Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 9.2 China Human Vaccine Contract Manufacturing Market Size by Type
  3. 9.2.1 China Human Vaccine Contract Manufacturing Market Size by Type (2021-2026)
  4. 9.2.2 China Human Vaccine Contract Manufacturing Market Size by Type (2027-2032)
  5. 9.2.3 China Human Vaccine Contract Manufacturing Market Share by Type (2021-2032)
  6. 9.3 China Human Vaccine Contract Manufacturing Market Size by Application
  7. 9.3.1 China Human Vaccine Contract Manufacturing Market Size by Application (2021-2026)
  8. 9.3.2 China Human Vaccine Contract Manufacturing Market Size by Application (2027-2032)
  9. 9.3.3 China Human Vaccine Contract Manufacturing Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 10.2 Asia Human Vaccine Contract Manufacturing Market Size by Type
  3. 10.2.1 Asia Human Vaccine Contract Manufacturing Market Size by Type (2021-2026)
  4. 10.2.2 Asia Human Vaccine Contract Manufacturing Market Size by Type (2027-2032)
  5. 10.2.3 Asia Human Vaccine Contract Manufacturing Market Share by Type (2021-2032)
  6. 10.3 Asia Human Vaccine Contract Manufacturing Market Size by Application
  7. 10.3.1 Asia Human Vaccine Contract Manufacturing Market Size by Application (2021-2026)
  8. 10.3.2 Asia Human Vaccine Contract Manufacturing Market Size by Application (2027-2032)
  9. 10.3.3 Asia Human Vaccine Contract Manufacturing Market Share by Application (2021-2032)
  10. 10.4 Asia Human Vaccine Contract Manufacturing Market Size by Country
  11. 10.4.1 Asia Human Vaccine Contract Manufacturing Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  13. 10.4.3 Asia Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  14. 10.4.4 Asia Human Vaccine Contract Manufacturing Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst